Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q2 2021 (← Previous) (Next →)

Filing Date: Aug 13, 2021

Total Value ($000): $677,000 (100.0% shares, 0.0% debt)

Holdings (9)

MDXG MIMEDX GROUP, INC. 43.2%

Value ($000) $292,442 Shares 23,376,623 Est. Cost $7.34 Unrealized +47.5%

BVS BIOVENTUS 31.4%

Value ($000) $212,902 Shares 12,096,702 Est. Cost $14.24 Unrealized +13.1%

— VENUS CONCEPT, INC. 5.7%

Value ($000) $38,620 Shares 12,417,856 Est. Cost $4.17 Unrealized —

EYPT EYEPOINT PHARMACEUTICALS INC 5.6%

Value ($000) $37,676 Shares 4,190,921 Est. Cost $4.68 Unrealized +105.1%

— REVANCE THERAPEUTICS INC 5.5%

Value ($000) $37,277 Shares 1,333,692 Est. Cost $31.50 Unrealized —

AXGN AXOGEN INC 4.1%

Value ($000) $27,588 Shares 1,276,645 Est. Cost $4.01 Unrealized +404.5%

TELA TELA BIO, INC. 3.8%

Value ($000) $25,455 Shares 1,580,089 Est. Cost $12.94 Unrealized +5.9%

MNOV MEDICINOVA INC 0.7%

Value ($000) $4,700 Shares 1,105,941 Est. Cost $2.95 Unrealized +46.1%

— CATALYST BIOSCIENCES INC 0.1%

Value ($000) $340 Shares 78,622 Est. Cost $7.36 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
MDXG	MIMEDX GROUP, INC.	23,376,623	$292,442	43.2%	$7.34	+47.5%	COM	602496101
BVS	BIOVENTUS	12,096,702	$212,902	31.4%	$14.24	+13.1%	COM CL A	09075A108
—	VENUS CONCEPT, INC.	12,417,856	$38,620	5.7%	$4.17	—	COM	92332W105
EYPT	EYEPOINT PHARMACEUTICALS INC	4,190,921	$37,676	5.6%	$4.68	+105.1%	COM NEW	30233G209
—	REVANCE THERAPEUTICS INC	1,333,692	$37,277	5.5%	$31.50	—	COM	761330109
AXGN	AXOGEN INC	1,276,645	$27,588	4.1%	$4.01	+404.5%	COM	05463X106
TELA	TELA BIO, INC.	1,580,089	$25,455	3.8%	$12.94	+5.9%	COM	872381108
MNOV	MEDICINOVA INC	1,105,941	$4,700	0.7%	$2.95	+46.1%	COM NEW	58468P206
—	CATALYST BIOSCIENCES INC	78,622	$340	0.1%	$7.36	—	COM NEW	14888D208